AbbVie Inc. Issuance/Purchase of Shares

Issuance/Purchase of Shares of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Issuance/Purchase of Shares growth rates and interactive chart.


Highlights and Quick Summary

  • Issuance/Purchase of Shares for the quarter ending September 29, 2019 was $-3 Million (a 50.0% increase compared to previous quarter)
  • Year-over-year quarterly Issuance/Purchase of Shares decreased by -99.85%
  • Annual Issuance/Purchase of Shares for 2018 was $-11.9 Billion (a 932.96% increase from previous year)
  • Annual Issuance/Purchase of Shares for 2017 was $-1.16 Billion (a -79.95% decrease from previous year)
  • Annual Issuance/Purchase of Shares for 2016 was $-5.77 Billion (a -22.42% decrease from previous year)
  • Twelve month Issuance/Purchase of Shares ending September 29, 2019 was $-2.67 Billion (a -27.31% decrease compared to previous quarter)
  • Twelve month trailing Issuance/Purchase of Shares decreased by -77.62% year-over-year
Trailing Issuance/Purchase of Shares for the last four month:
29 Sep '19 29 Jun '19 30 Mar '19 30 Dec '18
$-2.67 Billion $-3.68 Billion $-11.2 Billion $-11.9 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Issuance/Purchase of Shares of AbbVie Inc.

Most recent Issuance/Purchase of Sharesof ABBV including historical data for past 10 years.

Interactive Chart of Issuance/Purchase of Shares of AbbVie Inc.

AbbVie Inc. Issuance/Purchase of Shares for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $-3.0 $-2.0 $-616.0
2018 $-2,051.0 $-1,007.0 $-7,514.0 $-1,369.0 $-11,941.0
2017 $-465.0 $60.0 $59.0 $-810.0 $-1,156.0
2016 $-1,752.0 $35.0 $-3,716.0 $-332.0 $-5,765.0
2015 $-1,212.0 $-976.0 $-4,948.0 $-295.0 $-7,431.0
2014 $-245.0 $38.0 $18.0 $-244.0 $-433.0
2013 $-98.0 $56.0 $75.0 $-6.0 $27.0
2011 $0.0
2010 $0.0
2009 $0.0

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.